We'd need to know when the DSMB meets, i.e. when all the preparations for the meeting have been completed. A couple of days after, the company will be able to announce the outcome/recommendation.

With Mesoblast it was within days:

An independent Data Safety Monitoring Board (DSMB) has set a review date of early September for its first interim analysis of the Phase 3 trial of remestemcel-L in ventilator-dependent COVID-19 patients
with moderate to severe ARDS.

PR with recommendation to continue on September 4 .

http://investorsmedia.mesoblast.com/static-fi...66cd51b4d8